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Abstract: Background and Objective: The cardioprotective properties of Mediterranean Diet were 
demonstrated for the first time from the Seven Country Study. In the last few decades, numerous epi-
demiological studies, as well as intervention trial, confirmed this observation, pointing out the close 
relationship between the Mediterranean diet and cardiovascular diseases. In this context, extra virgin 
olive oil (EVOO), the most representative component of this diet, seems to be relevant in lowering the 
incidence of cardiovascular events, including myocardial infarction and stroke. From a chemical point 
of view, 98-99% of the total weight of EVOO is represented by fatty acids, especially monounsaturated 
fatty acids such as oleic acid. Tocopherols, polyphenols and other minor constituents represent the 
remaining 1-2%. All these components may potentially contribute to ”health maintenance” with their 
beneficial effects by EVOOO.  
Methods: Studies that examined the effect of EVOO supplementation in healthy subjects and in indi-
viduals at cardiovascular risk were included.  
Conclusion: The studies analyzed demonstrated the role of EVOO as anti-inflammatory, antioxidant 
and vasodilatory nutrient that may contribute to lower the atherosclerotic burden.
Keywords: Antioxidant, anti-atherosclerotic nutrient, endothelial dysfunction, extra virgin olive oil, cardiovascular disease, 
nutraceutical.
1. INTRODUCTION 
 Despite the new pharmaceutical therapies and the pro-
gress in the field of cardiovascular medicine, cardiovascular 
diseases (CVDs) represent the first cause of death in the 
Western world. More people die annually from CVDs than 
from any other cause. Significant changes in lifestyle, such 
as unhealthy diet, contribute to increased CVDs; therefore 
addressing behavioural risk factors can prevent most of 
them. In fact, many risk factors associated with the aetiology 
of cardiovascular disease are amenable to a nutraceutical 
approach, which refers to biologically active food-derived 
substances. This represents a powerful tool for maintaining 
health, counteracting the progressive incidence of CVDs.  
 The Mediterranean diet, the golden standard for healthy 
nutrition, is characterized by great intake of nutrients rich in 
polyphenols and is associated with reduced risk of cardio-
vascular events [1]. Among these nutrients, olive oil is uni-
versally recognized as a symbol of the Mediterranean diet: it 
represents the primary source of fat and has been associated  
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with a lower incidence of chronic heart diseases [2]. Based 
on the description and the definition reported in European 
Union Regulations [3], olive oils are classified, according to 
their quality, in extra virgin olive oil (EVOO), virgin olive 
oil (VOO) and ordinary olive oil (OO). EVOO is a virgin 
olive oil having a maximum free acidity in terms of oleic 
acid, of 0.8 g of acid per 100 g of oil; VOO is a virgin olive 
oil having a maximum free acidity of 2 g per 100 g; ordinary 
olive oil is an olive oil with acidity not more than 3.3%.  
 Special attention has been given to the compounds found 
in EVOO. The nutritional and healthy values, as well as the 
biological properties of EVOO, can be attributed to its bioac-
tive components including monounsaturated fatty acids 
(MUFAs) and polyunsaturated fatty acids, tocopherols, and 
polyphenols, in particular bio-phenols, which are the most 
represented. Among the beneficial properties of EVOO, its 
antioxidant effects have been intensively studied because of 
the link between oxidative stress and atherosclerotic diseases
[4]. Oxidative stress is implicated in the pathogenesis of sev-
eral risk factors of atherosclerosis including hypertension, 
diabetes and metabolic syndrome [4-6]. The aim of this re-
view is to highlight the role of EVOO in the atherosclerosis 
pathophysiology and its putative beneficial effects in the 
setting of cardiovascular disease.
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2. OXIDATIVE STRESS AND CARDIOVASCULAR 
DISEASES 
 Reactive oxygen species (ROS) includes 1) free radical 
species, that contains unpaired electrons and have strong 
oxidation ability such as superoxide anion (O2), peroxyni-
trite (ONOO), hydroxyl radical (HO) and 2) non-radicals 
species, such as hydrogen peroxide (H2O2), that is a longer-
lasting signalling molecule having oxidation ability. A vari-
ety of cell types, including vascular smooth muscle cells 
(VSMCs), endothelial cells, mononuclear cells and platelets, 
produce ROS using many enzymatic systems including 
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase, mitochondrial enzymes, uncoupled endothelial nitric 
oxide synthase (eNOS), and xanthine oxidase (XO). In the 
vascular system, several antioxidant mechanisms act to con-
trast ROS generation: superoxide dismutase (SOD), catalase, 
glutathione peroxidase (GPx), paraoxonase (PONs) and thi-
oredoxin (TRX) peroxidase. SOD rapidly dismutes O2 to 
H2O2, and then H2O2 is eliminated by GPx and converted 
into water. TRX is present in endothelial cells and VSMC 
and it can scavenge ROS such as H2O2 and ONOO. PON 
enzymes have peroxidase-like activity and protect against 
lipoprotein oxidation [7].  
 The imbalance between the ROS formation and the anti-
oxidant defence capability, in favour of pro-oxidant proc-
esses, is defined as oxidative stress. When endothelial cells 
become susceptible to oxidative stress, the activation of sev-
eral signalling cascades and redox- sensitive transcriptional 
factors induces endothelial dysfunction, leading to the devel-
opment of atherosclerosis (Fig. 1). 
3. OXIDATIVE STRESS AND ENDOTHELIAL 
DYSFUNCTION 
 The vascular endothelium plays a critical role in the 
pathophysiology of several vascular diseases and disorders. 
Under basal conditions, the endothelium regulates the traffic 
of macromolecules, the circulation of cells from blood to 
tissues and the maintenance of the vessel in a relatively neu-
tral state favouring dilatation over constriction [8]. An en-
hanced production of ROS and an attenuated antioxidant 
system would contribute to damage or excessively activate 
endothelial cells, causing the secretion of vasoconstrictor 
factors such as Angiotensin II, endothelin-1 (ET1) and nore-
pinephrine [9]. Conversely, ROS induce inactivation of nitric 
oxide (NO), a potent vasodilator and anti-aggregating mole-
cule [10]. 
 Changes of the endothelial redox state have a profound 
impact on endothelial NO availability. Endothelial NO pro-
duction derives from eNOS that utilizes L-arginine in the 
presence of oxygen, tetrahydrobiopterin (BH4), and reduced 
NADPH to produce NO and L-citrulline [10]. Oxidative 
stress could affect NO bioavailability by different mecha-
nisms: 1) increased O2- reacts rapidly with NO, resulting in 
the formation of the potent oxidant peroxynitrite (ONOO)
with consequent loss of NO bioactivity; 2) ROS promotes 
oxidative degradation of the critical eNOS cofactor BH4 
leading to “uncoupling” of the enzyme with reduced NO· 
and increased O2production [11].  
Fig. (1). Progression of atherosclerosis and cardiovascular dis-
ease mediated by oxidative stress and endothelial dysfunction. 
Traditional risk factors as hypertension, diabetes, and hypercholes-
terolemia are associated with a decrease in NO bioavailability and 
increase of radical species and promote oxidative stress and endo-
thelial dysfunction that play an important role atherosclerosis de-
velopment.  
 This pathologic state, characterized by compromised en-
dothelial responses, promotes platelet and leukocyte activa-
tion and adhesion and increases the permeability of the ves-
sel wall to oxidized lipoproteins and inflammation media-
tors. The consequent structural damage of the arterial wall 
determines atherosclerotic plaque formation. 
4. OXIDATIVE STRESS AND ATHEROSCLEROSIS 
 ROS play a key role in the atherosclerotic process that is 
a multistep and multifactorial pathological condition charac-
terized by a plethora of events occurring in the vascular wall, 
such as endothelial activation, macrophage infiltration and 
eventually plaque formation [12]. In this context, ROS medi-
ate different signalling pathways that promote vascular in-
flammation in atherogenesis from the initiation of fatty 
streak development through lesion progression to ultimate 
plaque rupture [13]. Increased oxidative stress in vascular 
cells promotes conversion of low-density lipoprotein LDL to 
more atherogenic oxidised LDL (ox-LDL). Oxidative modi-
fication of LDL cholesterol is the most biologically relevant 
modification that promotes atherosclerosis and that is re-
sponsible for the clinical events resulting from atherosclero-
sis. Moreover, ox-LDL itself represents a potent stimulus of 
vascular ROS formation increasing oxidative stress and con-
tributing to the inflammatory state of atherosclerosis [14].  
 Among different enzymatic pathways that can originate 
ROS in the vessel wall, NADPH oxidase (Nox) and in par-
ticular its isoform Nox2, is a key enzyme in the atheroscle-
rotic process. Nox2 is expressed in endothelial cells, adventi-
tial fibroblasts, inflammatory cells of developing atheroscle-
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rotic lesions and platelets. The role of Nox2 in atherosclero-
sis is supported by both humans and animal models [15-17]. 
5. INFLAMMATION AND ATHEROSCLEROSIS 
 In recent years, chronic inflammation has become recog-
nized as a contributory factor in the development of numer-
ous chronic diseases including CVD and the concept that 
inflammation plays a role in the initiation and progression of 
atherosclerosis is now well accepted [18]. There are different 
inflammatory cell types that play major roles in mediating 
the inflammatory response that is part of atherosclerosis in-
cluding T-cells, monocytes, and neutrophils [19]. The in-
flammatory response begins when lipid and lipoproteins are 
retained in the artery wall, especially when the lipids are 
oxidatively modified. These lipids and lipoproteins are taken 
up by macrophages, dendritic cells, and smooth muscle cells 
to form foam cells. The production and release of pro-
inflammatory cytokines and chemokines, such as tumour 
necrosis factor (TNF)-, interferons (IFNs), monocyte 
chemoattractant protein-1, stromal cell-derived factor-1, 
macrophage inflammatory protein-1, contribute to further 
elaborate the inflammatory response in the vessel wall. This 
pro-inflammatory status within the atherosclerotic lesion, in 
addition to oxidative stress, enhances atheroprogression [20]. 
6. EXTRA-VIRGIN OLIVE OIL (EVOO) AND 
REGULAR OLIVE OIL (ROO) 
 Many epidemiological studies, including randomised 
controlled trials, show that the intake of olive oil improves 
cardiovascular health [21]. The dietary intervention trial has 
demonstrated that an MD enriched with extra virgin olive oil 
has beneficial effects on blood pressure, glycaemic control in 
diabetics, endothelial function, oxidative stress and lipid 
profiles; in addition, it reduces susceptibility of LDL to oxi-
dation and concentrations of inflammatory markers such as 
C-reactive protein and IL-6 [22].  
 The benefits of olive oil have been related to its high con-
tent of MUFA and its richness in bioactive micro-
components such as polyphenols, abundant in virgin and 
extra-virgin olive oil but not in ordinary olive oil. 
 Guasch-Ferré et al., [2] in an observational study found 
that baseline total olive oil consumption, especially EVOO 
variety, was associated with a significant reduced risk of 
cardiovascular events and cardiovascular mortality in a 
Mediterranean population at high cardiovascular risk. They 
reported that increases of 10 g/d in EVOO intake were asso-
ciated with a 10% reduction in the risk of cardiovascular 
events. On the contrary, consumption of common OO was 
not significantly associated with cardiovascular morbidity 
and mortality [2].  
 The effects of olive oil with EVOO and without regular 
olive oil (ROO) antioxidant minor compounds were evalu-
ated on the levels of postprandial markers related to throm-
bogenesis and fibrinolysis, and triglycerides (TG) in healthy 
subjects. The results obtained highlighted that after 1-week 
lead-in dietary period, EVOO and ROO did not change fast-
ing plasma levels of TG, tissue factor (TF), fibrinogen, tis-
sue-type plasminogen activator (t-PA) and plasminogen acti-
vator inhibitor-1. However, the net incremental area under 
the curve (AUC) for haemostatic markers was significantly 
lower after the EVOO meal compared with the ROO meal. 
This study demonstrated the role of antioxidant minor com-
pounds from EVOO in the regulation of the postprandial 
haemostatic system and their cardioprotective effects [23]. In 
a previous study, same authors compared the effects of two 
diets enriched in olive oils, having the same fatty acid com-
position but with EVOO and without OO minor compounds, 
on postprandial accumulation of sICAM-1 and sVCAM-1 in 
healthy and hyper-triacylglycerolaemic subjects. They 
demostrated that the minor compounds of EVOO may re-
duce the release of sICAM-1 and sVCAM-1 after acute in-
take of a high-fat meal [24].  
 The comparison between EVOO and ROO was studied to 
evaluate the improvement of the lipid profile too. Ramirez-
Ramirez-Tortosa et al., [25] in a crossover design compared 
the effects of EVOO and ROO on plasma lipids and lipopro-
tein composition and LDL oxidation susceptibility in men 
with peripheral vascular disease. The LDL susceptibility to 
oxidation was significantly lower after the EVOO consump-
tion than after that of ROO. In addition, total LDL uptake by 
human macrophages was significantly greater in LDL iso-
lated when the patients consumed ROO rather than EVOO. 
This data suggests that antioxidants present in EVOO may 
protect LDL against oxidation more than OO does in men 
with peripheral vascular disease [25].  
7. THE EFFECT OF EVOO ON OXIDATIVE STRESS-
MEDIATED ENDOTHELIAL DYSFUNCTION AND 
ATHEROSCLEROSIS 
 The Mediterranean diet (MeDiet) is characterized by a 
high intake of EVOO, nuts, legumes, vegetables, fruit, fish, 
cereals and moderate wine consumption, with scarce intake 
of dairy products and red meat [26]. Many intervention stud-
ies showed that a Mediterranean dietary pattern, that includes 
EVOO, is strongly associated with a reduced risk of CVD 
[27]. Even if the molecular mechanisms exerted by EVOO 
are not fully understood, the healthy role of EVOO could be 
referred to its high level of MUFA and several biologically 
active phenolic compounds known to play important roles in 
cardiovascular protection [28]. 
 Considering the role of oxidative stress in the pathogene-
sis of atherosclerosis, a number of studies evaluated the anti-
oxidant effect of EVOO. Long and short-term studies sug-
gested that phenolic compounds are important for the car-
diovascular benefits of EVOO and showed an improvement 
of antioxidant capacity [29, 30] and a reduction of F2-
Isoprostane, ROS production and serum sNOX2-dp [31, 32], 
a marker of Nox2 activation. Moreover, EVOO supple-
mented to a Mediterranean lunch is capable of blunting oxi-
dative stress by regulating platelet oxidative stress and endo-
thelial dysfunction, as demonstrated by a reduction in Nox2 
activation and soluble E-selectin/VCAM1 release, respec-
tively [31]. 
 Soluble adhesion molecules such as E-selectin and P-
selectin, vascular cell adhesion molecule-1 (VCAM-1), and 
intercellular adhesion molecule-1 (ICAM-1) are predictors 
for endothelial dysfunction that represents an early marker of 
atherosclerosis events associated with cardiovascular risk 
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factors [33]. If after the short-term intervention with EVOO 
the comparison between groups reached statistical signifi-
cance neither for sE-selectin and sP-selectin nor for ICAM-1 
[34], Casas et al., [26] after 1 year of intervention with 
EVOO highlighted a decrease of soluble adhesion molecules 
such as P-selectin, VCAM-1 and ICAM-1. Moreover, in-
creased flow-mediated dilatation (FMD) [35], internal ca-
rotid intima-media thickness and plaque height [36] meas-
urements proved the ability of the MeDiet supplemented 
with EVOO to improve endothelial function. NO loss or 
reduction is associated with endothelial dysfunction. Data 
from long-term (1 year) intervention studies on subjects at 
high cardiovascular risk show that EVOO consumption is 
associated with an increase of NO availability [37, 38] and 
an upregulation of eNOS [37]. Conversely, Sala-Vila et al., 
[36] demonstrated that EVOO supplementation did not show 
any significant improvement of artery wall condition.
 Ox-LDL is a more potent pro-atherosclerotic factor than 
native unmodified LDL. ROS are able to begin lipid peroxi-
dation leading to activation of native unmodified LDL and 
formation of ox-LDL [39]. A decrease of ox-LDL was re-
ported in long-term studies (1 year) in subjects at high car-
diovascular risk after the virgin olive oil consumption com-
pared with the control group [40, 41]. In the EUROLIVE 
study, European participants were enrolled in a crossover 
study and were randomly assigned to three groups of olive 
oil differing in their phenolic content (low, medium and 
high) for three weeks. After olive oil intake, oxidized LDL 
levels decreased linearly with increasing phenolic content 
along with changes of other oxidative markers such as a re-
duction in C18 hydroxy fatty acid, conjugated dienes forma-
tion [42], plasma-F2isoprostanes production [43] and an im-
provement in the balance between reduced and oxidized glu-
tathione GSH and GSSG [42]. Moreover, olive oil promotes 
the generation of OxLDL autoantibodies, that have a protec-
tive role in atherosclerosis [44], while no changes in OxLDL 
and conjugated dienes were found [43].  
 The role of EVOO as anti-atherosclerotic nutrients is also 
supported by its ability to modulate human expressions of 
atherosclerosis-related genes in which LDL oxidation is in-
volved. After high polyphenol content (HPC; 366 mg/kg) in 
olive oil interventions (25 ml/day), a reduction in LDL oxi-
dation and in the expression of proatherogenic and proin-
flammatory genes related with the CD40/CD40L pathway is 
observed. This effect led to a reduction in the expression of 
its downstream products such as vascular endothelial growth 
factor- and monocyte chemoattractant protein-1, interleukin 
(IL)-8, and intercellular adhesion molecule-1 (ICAM1) via a 
decrease in Mitogen-Activated Protein Kinase-1 (MAPK1) 
activation [45]. The anti-inflammatory effect in the vascular 
wall may be another important mechanism that helps to ex-
plain the link between the EVOO and cardiovascular disease 
development. Casas R et al., [46] in their recent study evalu-
ated inflammatory markers like high-sensitivity C-reactive 
protein (hs-CRP), the levels of main cytokines (IL-1, 5, 6, 
7, 8, 12, TNF-, and IFN-) and vulnerability plaque marker 
(IL-10, 13, and 18) levels. They showed an improvement of 
these parameters in people having high cardiovascular risk 
long-term adherence, treated with MeDiet supplemented 
with EVOO, suggesting a delay in atheroma plaque forma-
tion [26, 46, 47]. Consumption of a Mediterranean-style 
diet supplemented with EVOO also in patients with the 
metabolic syndrome was associated a significant reduction 
of systemic vascular inflammation markers (IL-6, IL-7, IL-
18, and hs-CRP) [48]. Different results were reported after 
a short-term study (2 months) on subjects with abdominal 
obesity and without cardiovascular disease. In this study, 
the MeDiet supplemented with EVOO showed a beneficial 
tendency towards the down-regulation of some vascular 
inflammation markers (CRP and IL-6), however after the 
intervention, the comparison between groups did not reach 
statistical significance [34]. The intervention studies are 
summarized in Table 1.
 These results compared with long-term studies may sug-
gest that a longer period of dietary intervention may be re-
quired to modify concentration of the particular markers. 
While a significant decrease in inflammatory markers, 
namely Thromboxane-B2 (TXB2) and Leukotriene-B4, in 
both long- and short-term studies [30], EVOO supplementa-
tion confirmed the antithrombotic and anti-inflammatory 
effects of EVOO in a postprandial state too [29]. These 
mechanisms are depicted in Fig. (2).  
8. THE EFFECT OF EVOO ON CARDIOVASCULAR 
RISK FACTORS 
 Several factors, such as blood pressure, serum cholesterol 
and glucose, contribute to the development of atherosclerosis 
[59-61]. 
 Atherogenic stimuli like hypertension may activate the 
inflammatory response through oxidative stress by causing 
expression of mononuclear leucocyte recruiting mechanisms 
and may exert oxidative stress directly on the arterial wall 
and predispose to and accelerate atherosclerosis. The etiol-
ogy and development of hypertension are related to the im-
balance of vasodilation/vasoconstriction molecules released 
by endothelium, such as NO, a potent relaxing factor, and 
ET1 a potent vasoconstrictor. Mediterranean diet supple-
mented with EVOO for 1 year in non-smoking woman with 
moderate hypertension is able to increase serum NO along 
with changes in gene expression including 1) The up-
regulation of eNOS that keeps blood vessels dilated, controls 
blood pressure, and has numerous other vasoprotective and 
anti-atherosclerotic effects and 2) The down-regulation of 
caveolin 2 that binds eNOS resulting in stearic inhibition of 
the enzyme [37]. 
 In long-term studies on subjects at high cardiovascular 
risk, after supplemented EVOO MeDiet, the blood pressure 
values, both systolic and diastolic, are reduced [35, 37, 38]. 
The same results were recorded in a two-year study (2 years) 
on subjects with metabolic syndrome [48]. The results re-
ported in the studies of Storniolo et al., [37] are very interest-
ing where they showed a decrease in blood pressure values 
only in the moderate hypertensive group and not in the con-
trol group.  
 Nutritional interventions with EVOO are strong ap-
proaches to prevent the onset of a wide range of chronic dis-
eases including type 2 diabetes, obesity, and metabolic syn-
drome, due to their potential to ameliorate plasma glucose 
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Table 1. Extra Virgin Olive Oil (EVOO) effects on cardiovascular disease. The main characteristics and the main results of inter-
vention studies are reported. 
Treatment Dose 
Subjects N  
Healthy Status 
Study Design, 
Duration 
Markers References 
Extra virgin olive oil 1L/week 7447 
High cardiovascular 
risk 
Parallel, 
4.8 year 
- central obesity 
- high fasting glucose 
Babio et al. 2014 
[49] 
Extra virgin olive oil 50 ml 12  
Healthy subjects -Hydrogen 
peroxide levels 
Parallel,  
acute (1-2-6h) 
- TxB2
- LTB4
- Antioxidant capacity
- H2O2
Bogani et al. 2017 
[30] 
Extra virgin olive oil 10g  25 
Healthy subjects 
Cross-over, 
acute (2 h) 
Postprandial 
- ROS production
- serum sNOX2-dp
- 8-iso-PGF2a-III
Carnevale et al.
2014 [31] 
Extra virgin olive oil 
(MeDiet+ EVOO) 
1 liter/week 69 
High cardiovascular 
risk 
Parallel, 
 5 years 
- IL-6 , IL-8 , MCP-1 , MIP-1 
- IL-1 , IL-5 , IL-7 , IL-12p70 , IL-18 , TNF-
, IFN- , GCSF , GMCSF, ENA78 
Casas et al. 2017 
[26]  
Extra virgin olive oil 
(MeDiet+ EVOO) 
50 ml/d 165 
High cardiovascular 
risk 
Parallel, 
3-5 year 
- CRP 
- Interleukin-6,
- TNF- 
- HDL-cholesterol 
- Total cholesterol 
- LDL-cholesterol 
- Triglyceride 
- Blood pressure 
Casas et al. 2016 
[47]  
Extra virgin olive oil 
(MeDiet+ EVOO) 
50 mL/d 164 
High cardiovascular 
risk 
Parallel, 
 1 year 
- [sVCAM-1]  [sICAM-1] , [sP-selectin] 
- CRP , IL-6 , IL-18/IL-10 
Casas et al. 2014 
[46] 
Olive oil 25 ml/d 60 
Healthy subjects 
Cross over,  
3 weeks 
- Plasma OxLDL autoantibodies   Castaner et al.
2011 [44] 
Olive oil 25 ml/d 200 
Healthy subjects 
Cross over,  
3 weeks 
- HDL cholesterol 
- Total cholesterol/HDL-C 
- LDL-C/HDL-C 
- Triglycerides 
- Conjugated dienes , hydroxyl fatty acid , oxLDL 
Covas et al. 2006 
[42] 
Extra virgin olive oil 25 ml/d 60 
Healthy subjects  
Parallel,  
3 weeks 
- PON1
- Conjugated dienes
Cherki et al. 2005 
[50] 
Olive oil 25 ml/d 60 
Healthy subjects 
Cross over,  
3 weeks 
- Cholesterol 
- LDL cholesterol 
- Triacylglycerols 
- HDL cholesterol 
- Glucose 
- OxLDL 
- Conjugated dienes 
- Plasma Isoprostanes 
Cicero et al. 2008 
[43] 
Mediterranean Diet 
 (MeDiet+ EVOO) 
14.8 mL/d 137 
Healthy subjects 
Parallel, 
6 months 
- systolic blood pressure
- FMD
Davis et al. 2017 
[35] 
Olive oil 
(MeDiet + OO) 
8g/d 180 
Metabolic syndrome  
Parallel, 
2 years 
- Body weight , body mass index ,
waist circumference 
- Endothelial function score 
- Blood pressure
- Blood glucose and insulin, 
- Total cholesterol 
- triglycerides 
- HDL
- IL-6 , IL-7 , IL-18 , hs-CRP 
Esposito et al.
2004 [48] 
Table (1) contd…. 
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Treatment Dose 
Subjects N  
Healthy Status 
Study Design, 
Duration 
Markers References 
Extra virgin olive oil 25 ml/d 3985 
High cardiovascular 
risk 
Parallel, 
5 year 
- Bodyweight 
- Waist circumference
Estruch et al. 2016 
[51] 
Extra virgin olive oil 25g 183 
Obese  
Acute-
Postprandial 
3,5 h 
- Insuline
- C-peptide
Farnetti et al. 2013
[52] 
Virgin olive oil  5L/month 930 
High cardiovascular risk 
Parallel, 
1 year 
- ox-LDL Fitó et al. 2014 
[41] 
Virgin olive oil 1 L/week 210 
High cardiovascular 
risk 
Parallel, 
1 year 
- LDL resistance against oxidation 
- ox-LDL 
Hernáez et al.
2017 [40] 
Virgin olive oil 1 L/week 296 
High cardiovascular 
risk 
Parallel, 
1 year 
- HDL oxidative status and composition  Hernáez et al.
2017 [53] 
Extra virgin olive oil 
and Corn oil 
54g/d 54 
Healthy subjects 
Crossover, 
21 days 
- HDL , VLDL 
- LDL
- APO-B E , APO-A1
Maki et al. 2017 
[54] 
Extra virgin olive oil 1L/week High cardiovascular 
risk 
Parallel, 
1 year 
- Systolic/diastolic blood pressure 
- Plasma NO 
Medina-Remón  
et al. 2015 [38] 
Extra virgin olive oil 1L/week 110 
Metabolic syndrome 
Parallel, 
1,5 years 
- Urine levels of F2-Isoprostane 
- DNA damage base (8-oxo-7,8- dihydro-20-
deoxyguanosine;8-oxo-dG) 
Mitjavila et al.
2013 [32] 
Extra virgin olive oil 45 ml/d 90 
Abdominal obesity 
Parallel, 
2 months 
- CRP, IL-6 
- sP-selectin, sE-selectin 
- ICAM-1
Rallidis et al. 2017
[34] 
Extra virgin olive oil 1L/week 2866 
High cardiovascular risk 
Parallel, 
1 year 
- Glycemic index
- Glycemic load
Rodríguez-Rejón 
et al. 2014 [55] 
Extra virgin olive oil 30g/d  175 
High carotid atherosclerotic 
burden  
Parallel, 
2,4 years 
- internal carotid intima-media  
thickness 
- plaque height 
Sala-Vila et al.
2014 [36] 
Extra virgin olive oil  60 
Moderate hypertension 
Parallel 
1 year 
- Serum NO 
- Blood pressure 
Storniolo et al.
2016 [37] 
Extra virgin olive oil 1L/week 7158 
High cardiovascular risk  
Parallel, 
4,8 years 
- Systolic blood pressure
- Diastolic blood pressure
Toledo et al. 2013 
[56] 
Extra virgin olive oil 10g 25 
Healthy subjects 
Cross-over, 
acute (2 h) 
Postprandial 
- Blood glucose 
- DPP-4 protein and activity 
- LDL-C , ox-LDL 
- insulin , GLP-1 , GIP 
Violi et al. 2015 
[57] 
Extra virgin olive oil 40ml/d 22 
Mild Dyslipidemia  
Crossover, 
4 weeks 
- TBX2 
- 8-iso-PGF2a 
- Antioxidant capacity 
Visioli et al. 2005 
[30] 
Extra virgin olive oil 
(MeDiet + EVOO) 
1 L/week 231  
High cardiovascular 
risk 
Parallel, 
1 year 
- Plasma tryptophan  Yu et al. 2017 [58]
10    Endocrine, Metabolic & Immune Disorders - Drug Targets, 2018, Vol. 18, No. 1 Nocella et al.
Fig. (2). The role of EVOO in the atherosclerosis pathophysiology. EVOO shows a positive effect on several aspects of cardiovascular 
disease through its antioxidant, anti-inflammatory and anti-platelet aggregation properties. EVOO is a potent antioxidant that may reduce 
intracellular ROS production. It may also enhance SOD activity, hence decreasing O2 levels. Moreover, is able to reduce lipid peroxidation 
and scavenge intracellular ROS and free NO, reducing the formation of OONO. EVOO explicate its anti-inflammatory activity modulating 
the levels of adhesion molecules and eicosanoids, the expression of inflammatory cytokines and the expression of COX.  
and lipids. Changes of glycaemic and lipid profile might 
have an effect on cardiovascular disease by promoting or 
aggravating the atherosclerotic process. MeDiet supple-
mented with EVOO has a beneficial effect on the post-
prandial metabolic profile by decreasing blood glucose, 
LDL-C and ox-LDL and increasing insulin levels in healthy 
subjects [57]. Furthermore, 10 g of EVOO supplemented to a 
Mediterranean lunch are able to improve post-prandial gly-
caemic profile in patients with impaired fasting glucose. The 
mechanisms accounting for the positive effect of EVOO are 
related to incretins up-regulation, as EVOO reduces dipepti-
dyl peptidase-4 activity with consequent increase in gluca-
gon-like peptide-1 concentration which regulates post-
prandial glycaemia by up-regulating insulin secretion [62].  
 Hypercholesterolemia is another risk factor for CVD. 
MeDiet, thanks to its components, has been associated with a 
reduction in atherogenic cholesterol LDL-C and non-high-
density lipoprotein cholesterol (non-HDL-C) levels [63]. 
Hernáez et al., [40] in their study showed that 1 year of in-
tervention with a MeDiet, especially when enriched with 
virgin olive oil, improves several HDL functions such as 
cholesterol efflux capacity, cholesterol metabolism, antioxi-
dant/anti-inflammatory properties, and vasodilatory capacity, 
in individuals at high cardiovascular risk. Similarly, Covas et
al., [42] found that after consuming phenolic olive oils, 
HDL-C increased whereas TC/HDL-C ratio decreased with a 
decrease in LDL-C/HDL-C ratio and triglycerides.  
 Changes in glycaemic and lipid profile were observed 
also in patients with the metabolic syndrome. After 2 years, 
patients in the intervention group (MeDiet supplemented 
with EVOO) had significant decreases in the levels of glu-
cose, insulin, total cholesterol, and triglycerides and a sig-
nificant increase in the levels of HDL, all of which were 
greater than the control group. These data suggest that a 
Mediterranean-style diet is a possible strategy for the treat-
ment of metabolic syndrome and to reduce the associated 
cardiovascular risk [48]. 
 In short-term intervention studies, the intake of EVOO 
does not improve lipidic profile. In fact, in crossover-study 
of 21 days on 54 healthy subjects, the total cholesterol, LDL-
C, VLDL-C, APOB, APOA and LDL particle concentrations 
were improved by corn oil to a greater extent compared with 
EVOO intake [54]. 
CONCLUSION 
 The data reported here indicate that EVOO intake is as-
sociated with a beneficial impact on CVDs. Interventional 
studies are consistent with these beneficial effects, as sup-
ported by the ability of EVOO to prevent or reduce the in-
flammatory processes associated with chronic-degenerative 
diseases, such as cardiovascular-cerebral diseases and can-
cer. The implications and the perspectives of the intake of 
EVOO are evident considering its role in modulating post-
	
	


	









	
  


!"#
	
$
 #
!%%&'
"((%
$%&)*+
+,%
-) 


-)
-) .
.

%&+
%%
$%&'%/
%%
	01
	01
 %&+ " %&+
2*
!	$
,,%
"+/%&)
	3
$$
$4%
$4%///



"

5
-
	01
1))
))
#  -
Extra Virgin Olive Oil and Cardiovascular Diseases Endocrine, Metabolic & Immune Disorders - Drug Targets, 2018, Vol. 18, No. 1    11
prandial hyperglycaemia and hyperlipidaemia and in particu-
lar their impact on vascular diseases. Indeed, in the onset of 
diabetes, EVOO supplementation provides an improvement 
of post-prandial glucose and lipid profile; this effect repre-
sents a new mechanism supporting the role of EVOO as an 
anti-atherosclerotic nutrient. The intake of EVOO, in conclu-
sion, represents a simple but effective nutritional approach to 
modulate the deleterious effect of different cardiovascular 
risk factors, such as oxidative stress, inflammation, post-
prandial hyperglycaemia and hyperlipidaemia, on the vascu-
lar system. 
LIST OF ABBREVIATIONS 
AUC = Area under the curve  
BH4 = Tetrahydrobiopterin  
CVDs = Cardiovascular diseases  
eNOS = Endothelial nitric oxide synthase  
ET1 = Endothelin-1  
EVOO = Extra virgin olive oil  
FMD = Flow-mediated dilatation  
GLP1 = Glucagon-like peptide-1  
GPx = Glutathione peroxidase  
HDL = High-density lipoprotein  
HO = Hydroxyl radical  
H2O2 = Hydrogen peroxide  
hs-CRP = High-sensitivity C-reactive protein  
ICAM-1 = Intercellular adhesion molecule-1  
IFN- = Interferon gamma  
IL = Interleukin  
LDL = Low-density lipoprotein  
MAPK1 = Mitogen-activated protein kinase-1  
MeDiet = Mediterranean diet  
MUFAs = Monounsaturated fatty acids  
NADPH = Nicotinamide adenine dinucleotide phos-
phate  
NO = Nitric oxide  
Nox = NADPH oxidase  
O2 = Superoxide anion  
ONOO = Peroxynitrite  
ox-LDL = Oxidised low-density lipoprotein  
PONs = Paraoxonase  
ROO = Regular olive oil  
ROS = Reactive oxygen species  
SOD = Superoxide dismutase  
TF = Tissue factor  
TRX = Thioredoxin  
TG = Triglyceride  
TNF- = Tumor necrosis factor  
t-PA = Tissue plasminogen activator  
TXB2 = Thromboxane-B2  
VCAM-1 = Vascular adhesion molecule-1  
VSMCs = Vascular smooth muscle cells  
XO = Xanthine oxidase  
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